Te cervical cancer vaccine from GSK has been granted a licence by the Therapeutic Goods Administration (TGA) of Australia for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types. Cervarix is now approved in Australia for use in females aged 10 to 45 years old. This is the first major market licence for Cervarix, GSK's cervical cancer vaccine.

"The approval of Cervarix in Australia is a key milestone towards eradicating the burden of cervical cancer for all women, especially as this is the first cervical cancer vaccine that is explicitly indicated anywhere in the world for women over the age of 26. This vaccine heralds a major scientific breakthrough in cervical cancer prevention and demonstrates GSK's commitment to developing innovative vaccines. It is great news for us and this vaccine will be a key driver in GSK's future growth," said Jean Stephenne, president of GlaxoSmithKline Biologicals.

Cervarix is formulated with a novel proprietary adjuvant system called AS04 which is designed to enhance immune response and increase the duration of protection. Published data have shown that this adjuvant formulation provides a stronger and longer-lasting immune response compared to the same vaccine composition formulated with conventional aluminum hydroxide adjuvant alone. Jean Stephenne added, "We are especially excited about Cervarix, the first cervical cancer vaccine to feature one of our novel adjuvant systems. Our goal is to provide the best possible protection for women against cervical cancer."

Cervarix has been tested in over 40,000 females in clinical trials and, in these trials, Cervarix showed consistently high levels of efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 181. In findings from these clinical trials, Cervarix has been shown to have a good safety profile and to be generally well-tolerated in women. Data also showed preliminary evidence of additional protection against infection with cancer-causing virus types other than virus types 16 and 181.

GSK submitted a Biologics Licence Application (BLA) for Cervarix to the US Food and Drug Administration (FDA) in March 2007, following earlier regulatory filings with the European Medicines Agency(EMEA) and regulatory filings in Africa, Asia and Latin America.

Cervical cancer is the second leading cause of cancer in women under 45, and causes over 270,000 deaths worldwide per year. It occurs when infection with the human papillomavirus becomes persistent, and progresses to cancer. Up to 50-80 per cent of women will acquire an infection in their lifetime, with the risk of persistence increasing with age. This is why it is so important to ensure that women over 26 are also protected against cancer-causing virus types, to reduce the risk of infection becoming persistent and progressing to cervical cancer. In humans, approximately 100 types of HPV have been identified to date and, of these, approximately 15 virus types are considered to cause cervical cancer. Virus types 16 and 18 are responsible for approximately 70 percent of cervical cancers globally.